Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Gemin X Pharmaceuticals

Request full access

Develops and commercializes targeted cancer therapeutics to improve the lives of patients

Malvern, United StatesFounded 1997Biotech & Life Sciences

About Gemin X Pharmaceuticals

Gemin X Pharmaceuticals was a biopharmaceutical company focused on the development of targeted cancer therapeutics. The company was founded in 1998 as a spin-out from McGill University, with research operations in Montréal, Canada, and executive headquarters in Malvern, Pennsylvania. A key figure in the company's later stage was Glenn J. Gormley, M.D., Ph.D., who joined as President and CEO in June 2008, bringing extensive experience from leadership roles at Novartis, AstraZeneca, and Merck.

The company's core business revolved around creating drugs that reinitiate programmed cell death (apoptosis) and inhibit the metabolism of cancer cells. This approach targeted a variety of hematological and solid tumors. Gemin X's business model was centered on the research and clinical development of its pipeline candidates, with the ultimate goal of commercialization, likely through partnerships or acquisition by a larger pharmaceutical entity. The company successfully raised significant capital through multiple funding rounds, totaling over $100 million by mid-2008 to finance its clinical trials.

Gemin X's product pipeline included several promising candidates. The lead product, obatoclax (GX15-070), was a pan-Bcl-2 inhibitor designed to restore the natural cell death process in cancer cells. It was in Phase II clinical trials for treating conditions like extensive-stage small cell lung cancer (SCLC) and acute myeloid leukemia (AML). Another significant asset was teglarinad (GMX1777), a novel inhibitor of NAD+ synthesis, which had completed Phase 1 studies. The company also had a preclinical telomere capping program.

A major milestone occurred in March 2011, when Cephalon, Inc. announced a definitive agreement to acquire Gemin X for $225 million in cash. The deal also included potential future payments of up to $300 million based on regulatory and sales milestones, bringing the total potential value to $525 million. The acquisition was completed in the second quarter of 2011, at which point Gemin X became a wholly-owned subsidiary of Cephalon.

Source: Dealroom company data

At a glance

Founded
1997
Headquarters
Malvern, United States
Sector
Biotech & Life Sciences

Gemin X Pharmaceuticals in the Malvern ecosystem

Live from Dealroom

The Gemin X Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later10 investors entered at this stage

  • Caxton Advantage Life Sciences Fund
  • HBM Partners
  • ProQuest Investments
  • Fonds de solidarité FTQ
  • Merlin Biomed
  • SB Life Science
  • VantagePoint Capital Partners
  • Pinnacle Ventures
  • HIG Capital
  • Sanderling Ventures
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Malvern HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Gemin X Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gemin X Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.